CAS No. : 186692-46-6

(Synonyms: CYC202; R-roscovitine; Seliciclib)

Price and Availability of CAS No. : 186692-46-6
Size Price Stock
10mg $72 In-stock
50mg $180 In-stock
100mg $240 In-stock
200mg $336 In-stock
500mg $708 In-stock
1g $1104 In-stock
5 g Get quote
10 g Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-30237
M.Wt: 354.45
Formula: C19H26N6O
Purity: >98 %
Storage: at 20℃ 2 years
Solubility: 10 mM in DMSO
Introduction of 186692-46-6 :

Roscovitine is a potent and selective CDK inhibitor with IC50 of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively. IC50 & Target: IC50: 0.2 μM (CDK5), 0.65 μM (Cdc2), 0.7 μM (CDK2)[1] In Vitro: Roscovitine displays high efficiency and high selectivity towards some cyclin-dependent kinases. The kinase specificity of Roscovitine is investigated with 25 highly purified kinases (including protein kinase A, G and C isoforms, myosin light-chain kinase, casein kinase 2, insulin receptor tyrosine kinase, c-src, v-abl). Most kinases are not significantly inhibited by Roscovitine. Cdc2, Cdk2, and Cdk5 only are substantially inhibited (IC50 values of 0.65, 0.7, and 0.2 μM, respectively). Cdk4k and Cdk6 are very poorly inhibited by Roscovitine (IC50>100 μM). Extracellular regulated kinases erk1 and erk2 are inhibited with an IC50 of 34 μM and 14 μM, respectively. Roscovitine inhibits the proliferation of mammalian cell lines with an average IC50 of 16 μM[1]. Roscovitine decreases the level of CDK5 and p35 with upregulation of E-cadherin, but downregulation of Vimentin and Collagen IV. Moreover, Roscovitine inhibits the ability of high glucose cultured NRK52E cells to migrate and invade[2]. In Vivo: Compare with normal controls, Roscovitine downregulates phosphorylated ERK1/2 and PPARγ with concomitant increase in E-cadherin, but decrease in Vimentin and Collagen IV. Correspondingly, Roscovitine decreases renal tubulointerstitial fibrosis of diabetic rats. Roscovitine is effective in decreasing tubulointerstitial fibrosis via the ERK1/2/PPARγ pathway in diabetic rats[2]. Roscovitine (16.5 mg/kg) significantly reduces the rate of tumor growth and increases survival of treated mice. Strikingly, Roscovitine treatment leads to complete tumor disappearance in one mouse (25%); moreover, no tumor regrowth in this mouse is found 5 months after completion of the treatment. Mouse weights do not differ significantly between mice treated with Roscovitine and control mice, and behavioral differences between the two groups are also negligible. These results suggest that Roscovitine can be used effectively as a selective tumor growth inhibitor in HPV+ head and neck cancer[3].

Your information is safe with us.